 |
|
|
| |
Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH
|
| |
| |
CROI 2023 Feb 20-23
Onyema Ogbuagu,1* Sorana Segal-Maurer,2 Antonella Castagna,3 Edwin DeJesus,4 Anchalee Avihingsanon,5 Christine Zurawski,6 Olayemi Osiyemi,7
Theo Hodge,8 Gordon E. Crofoot,9 Hui Wang,10 Hadas Dvory-Sobol,10 Martin S. Rhee,10 Jared Baeten,10 Jean-Michel Molina11
1Yale School of Medicine, New Haven, CT; 2New York-Presbyterian Queens, Flushing, NY; 3Università Vita-Salute San Raffaele, Milano, Italy; 4Orlando Immunology Center, Orlando, FL; 5HIV-NAT: The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 6Atlanta ID Group, Atlanta, GA; 7Triple O Research Institute P A., West Palm Beach, FL; 8Washington Health Institute, Washington, DC; 9 The Crofoot Research Center, Houston, TX; 10Gilead Sciences, Inc., Foster City, CA; 11Université Paris Cité, Hôpital Saint-Louis/Hôpital Lariboisière, Paris, France
|
| |
|
|
|
|
|
